EMA gives regulatory nod for world’s first malaria vaccine, Mosquirix
European Medicines Agency has cleared the final regulatory hurdle for Mosquirix after the drug has been under research for more than 30 years, detailed in 2,30,000 pages of data
World’s first vaccine for Malaria might just see the light of the day, with the European Medicines Agency giving it a green signal. Crossing the final regulatory hurdle in a positive scientific opinion at EMA, Mosquirix will now seek an approval from WHO. Post, the drug will be made available across the African nations to many children affected by Malaria in the Sub-Saharan regions.
The approval by WHO is likely to come in November this year, after a careful examination by the WHO. The drug saw the green lights from EMA after 30 years of long research, detailed in 2,30,000 pages on data. WHO is set to review the feasibility of the drug in context of its field application in developing countries, considering the affordability, quality, and its cost effectiveness.
As reported by PTI,
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.